Oncology Archives - DelveInsight

Oncology

bispecific-antibodies
Rise In Bispecific Antibodies Utilization As Antibody Therapeutics

Bispecific Antibodies (BsAbs) are antibodies that contain two different antigens or have two different epitopes on the same antigen. It is observed for Bispecific Antibodies in clinical trials tha...


AACR 2022 KRAS
AACR 2022: Novartis shifting focus towards directly targeting KRASG12c after disappointment from ...

Post Lumakras ‘approval,  Adagrasib’s PDUFA date, Novartis now ready to enter the KRASG12C space Novartis is now heading towards its unique KRASG12C inhibitor in patients with advanced non-smal...


AACR 2022 - LAG 3 Immunotherapy
AACR 2022: LAG-3, one of the most trending Next-generation Immunotherapy

Updates on F-star Therapeutics’ and Akeso’s Bi-specific Antibody targeting LAG-3 and PD-L1 F-star Therapeutics presented the preclinical mechanistic data on the Novel LAG-3 Reduction and Sheddi...


ASCO GU 2022 - Urothelial Carcinoma
Data readout of potential ADCs: Enhertu gears up for Urothelial Carcinoma Market now

Enhertu with Opdivo exhibited clinical efficacy with an ORR of 36.7% in HER2+ urothelial cancer in Phase Ib study On the second day of ASCO-GU 2022, the rapid abstract session highlighted the r...


PARP Inhibitors in Urothelial Carcinoma
PARP inhibitors in Urothelial carcinoma (UC): Hit or miss?

Chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates are being used for treating Urothelial Carcinoma(UC) patients and now PARP inhibitors are being studied...


Renal Cell Carcinoma Highlights- ASCO
ASCO GU 2022: Renal Cell Carcinoma Highlights

Phase II study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma Based on the findings from the Phase II study (NCT04022343), neoadjuv...


Bladder Cancer Highlights ASCO
Seagen/Astellas plans to expand their Antibody Drug Conjugate (ADC), Padcev in additional bladder...

Padcev (Enfortumab vedotin) for the treatment of locally advanced or metastatic urothelial cancer, Adcetris (Brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas, a...


Chimeric antigen receptor T cell (CART) Treatment
With early-stage data, Chimeric antigen receptor T cell (CART) finding its way towards entering P...

Use of CAR-T treatments and their efficacy in Prostate Cancer We already know that Immunotherapies have not performed well in the treatment of prostate cancer. Such medicines have failed to eli...


Arvinas’s mCRPC ASCO
Early but strong clinical data of Arvinas’s ARV-110 in Men with mCRPC that support a potential pa...

Major Key player Arvinas announced completed Phase I and interim Phase II ARDENT data for ARV-110 degrader targeting the androgen receptor (AR). According to the results, Arvinas mentioned that at...


ASCO GU 2022
PARP inhibitors making inroads towards the first line metastatic Castrate-resistant prostate canc...

Delveinsight brings you the comparative analysis on Positive Phase III trial results of PARP inhibitors, Zejula (Niraparib) and Lynparza (Olaparib) in metastatic CRPC patient population. PARP i...


Editor's Pick
Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU ...

Patent protection and expiration is one of the hot topics in the healthcare industry. P...

What are the Top 9 Most Common Food Allergies and How Pharma Companies are Ta...

Food Allergies is a major concern for a wide spectrum of populations globally. Accordin...

Evaluating the Top Players in the Global Bone Densitometers Market

Bone densitometers are the diagnostic systems with an enhanced X-ray technology known a...

Mapping the Biggest Pharmaceutical Companies by Continents

Today, the most important factor affecting the world’s economy is the Global Pharmaceut...

Robotic Surgery: Navigating the Growing Demand, Ongoing Trends & Develop...

It's no longer startling to learn that the best-performing surgeon at a hospital isn't ...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.